Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.0200 (-2.9%) ($5.9800 - $6.3600) on Mon. Jul. 1, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.21% (three month average) | RSI | 88 | Latest Price | $6.0200(-2.9%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.8% a day on average for past five trading days. | Weekly Trend | ADMS advances 14.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(11%) LQD(6%) SHY(6%) VCIT(6%) UNG(5%) | Factors Impacting ADMS price | ADMS will decline at least -1.605% in a week (0% probabilities). INDA(-8%) BNDX(-7%) XLE(-6%) USO(-6%) URA(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.605% (StdDev 3.21%) | Hourly BBV | 0 () | Intraday Trend | -3.8% | | | |
|
5 Day Moving Average | $5.98(0.67%) | 10 Day Moving Average | $5.71(5.43%) | 20 Day Moving Average | $5.19(15.99%) | To recent high | -16.9% | To recent low | 19.2% | Market Cap | $170m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |